Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808

Press Releases

SAN DIEGO – July 13, 2017 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded a Phase IIB Small Business Innovation Research (SBIR) grant of up to $2.8 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of…

read more

Crinetics Pharmaceuticals Appoints Ajay Madan as Vice President, Development

Press Releases

SAN DIEGO – June 6, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders, announced today the addition of Ajay Madan, Ph.D., D.A.B.T. as Vice President, Development. “We continue to strategically assemble a world-class team with deep expertise in discovering and developing innovative therapeutics,” said Scott Struthers, Ph.D., Founder and…

read more

Crinetics Pharmaceuticals Completes $40 Million Series A Financing

Press Releases

SAN DIEGO – November 2, 2015 – Crinetics Pharmaceuticals, an innovative therapeutics company focused on specialty endocrine disorders, announced today the completion of a $40 million series A financing led by 5AM Ventures, Versant Ventures, and Vivo Capital. Crinetics plans to use the proceeds to advance development of its small molecule somatostatin agonist program to…

read more

Crinetics Pharmaceuticals Appoints Matt Fust, M.B.A., David Clemons, M.D., and John Wallen, Ph.D., J.D. as Corporate, Clinical, and Legal Advisers

Press Releases

SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today the addition of corporate, clinical, and legal advisers as the company prepares for the clinical development of its pipeline of first- and best-in-class medicines. Matt Fust will serve as a corporate adviser. Mr….

read more

Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain

Press Releases

SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today that it has been awarded Phase I of a Fast-Track Small Business Innovation Research (SBIR) grant of up to $2.7MM from the National Institute of Neurological Disorders and Stroke (NINDS) of the National…

read more

Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women’s Health Diseases

Press Releases

SAN DIEGO — January 28, 2015 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $1.5 MM Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) for the development of orally-available,…

read more

Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases

Press Releases

SAN DIEGO — April 28, 2014 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to explore the use of its oral, small molecule somatostatin receptor agonist drug candidates for…

read more

Crinetics Pharmaceuticals Awarded National Institutes of Health Small Business Innovative Research Grant to Develop GPCR Biosensors for Drug Discovery

Press Releases

SAN DIEGO — February 7, 2009 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop G protein-coupled receptor (GPCR) biosensors for drug discovery applications. The grant supports the Company’s effort to expand this cutting-edge…

read more